Germany - Drugs

Description

IKK classic hereby announces that it will conclude non-exclusive discount agreements with all interested and suitable pharmaceutical companies in the period from 01.05.2023 to 30.04.2025 for various active ingredients and combinations of active ingredients on equal, non-negotiable terms in accordance with Section 130a (8) of the German Social Code Book V. The earliest contract start date is 01.05.2023, provided that the signed contract and all necessary evidence, self-declarations and documents are received by IKK classic by 03.04.2023. Thereafter, the following applies: If the documents are received by the 05th of a respective month in the possible accession period, the contract will start on the 01st of the following month. If the documents are received after the 5th of the respective month in the possible accession period, the contract will begin on the 1st of the month after the next. Accession to the agreement is possible at any time during the specified period, but no later than 05.03.2025. For further details, see section VI.3).
Apomorphine; ATC code: N04BC07 Baclofen; infusion solution; ATC code: M03BX01 Benserazide and levodopa; sustained-release capsules; ATC code: N04BA11 betamethasone and gentamicin; ATC code: D07CC01 brimonidine; single-dose pipettes; ATC code: S01EA05 cariprazine; ATC code: N05AX15 deferoxamine; ATC Code: V03AC01 dydrogesterone and estradiol; ATC code: G03FA14 or G03FB08 formoterol and aclidinium bromide; ATC code: R03AL05 indacaterol and mometasone; ATC code: R03AK14 indacaterol, glycopyrronium bromide, and mometasone; ATC code: R03AL12 lamivudine and dolutegravir; ATC code: J05AR25 oxybutynin; transdermal patches; ATC code: G04BD04 Prednisolone; ocular use; ATC code: S01BA04 Raltegravir; ATC code: J05AJ01 rifampicin; ATC code: J04AB02 Vemurafenib; ATC code: L01EC01

Opportunity closing date

05 March 2025

Value of contract

£0-100k